M3 Group extends reach in Iberian and Latin American markets with partnership

Share this article:
Aki Tomaru
Aki Tomaru

MDLinx owner M3 Group is partnering with Argentine online CME firm Medcenter on a content-sharing deal that will expand its in-language reach to Spain, Portugal and Latin America.

Medcenter will join M3's Networks in Health, an “international alliance of online physician communities that provides pharmaceutical, medical device and other healthcare companies services for reaching and engaging doctors across Europe, the Americas and Asia.”

“We're trying to be global,” said Aki Tomaru, CEO of M3 USA. Tomaru said that while M3's Doctors.net.uk runs pan-European campaigns, pharmas are increasingly shopping for broader buys that hopscotch across global markets.

“They want to cherry-pick the countries,” said Tomaru. Until now, he added, that meant either partnering with a different in-culture shop in each country or distributing their content in English through WebMD's Medscape (with which Medcenter had a previous affiliation). “The willingness of most physicians in non-English-speaking countries to spend time on English language materials is limited,” said Tomaru.

Medcenter boasts a network of 480,000 physicians. M3, a Sony-owned Japanese conglomerate whose portfolio includes M3.com in Japan, US-based MDLinx and UK-based Doctors.net.uk, claims more than a million physician members worldwide.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union